Literature DB >> 32529478

Regulation of tumor infiltrated innate immune cells by adenosine.

Regina Strakhova1, Octavia Cadassou1, Emeline Cros-Perrial1, Lars Petter Jordheim2.   

Abstract

Cancer has the ability to escape the immune system using different molecular actors. Adenosine is known to be involved in mechanisms which control inflammatory reactions and prevent excessive immune response. This purine nucleoside can be translocated from the cell or produced in the extracellular space by 5'-ectonucleotidases. Once bound to its receptors on the surface of immune effector cells, adenosine activates various molecular pathways, which lead to functional inhibition of the cell or its death. Some tumors are infiltrated by the different cells of immune system but are able to use adenosine as an immunosuppressive molecule and thus inhibit immune anticancer response. This mechanism is well described on adaptive cells, but much less on innate cells. This review outlines major effects of adenosine on innate immune cells, its consequences on cancer progression, and possible ways to block the adenosine-dependent immunosuppressive effect.

Entities:  

Keywords:  Adenosine; Cancer; Dendritic cells; Inflammation; Macrophages; Mast cells; Microenvironment; NK cells; Neutrophils

Year:  2020        PMID: 32529478      PMCID: PMC7524890          DOI: 10.1007/s11302-020-09701-6

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  45 in total

1.  Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice.

Authors:  G Haskó; C Szabó; Z H Németh; V Kvetan; S M Pastores; E S Vizi
Journal:  J Immunol       Date:  1996-11-15       Impact factor: 5.422

Review 2.  Regulation of macrophage function by adenosine.

Authors:  György Haskó; Pál Pacher
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04       Impact factor: 8.311

3.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

4.  Adenosine-mediated inhibition of the cytotoxic activity and cytokine production by activated natural killer cells.

Authors:  Anna Lokshin; Tatiana Raskovalova; Xiaojun Huang; Lefteris C Zacharia; Edwin K Jackson; Elieser Gorelik
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

Review 5.  Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?

Authors:  V Kumar
Journal:  Purinergic Signal       Date:  2012-12-28       Impact factor: 3.765

Review 6.  Targeting NKG2A to elucidate natural killer cell ontogenesis and to develop novel immune-therapeutic strategies in cancer therapy.

Authors:  Elisa Zaghi; Michela Calvi; Emanuela Marcenaro; Domenico Mavilio; Clara Di Vito
Journal:  J Leukoc Biol       Date:  2019-01-15       Impact factor: 4.962

7.  Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages.

Authors:  Emilie Velot; Benjamin Haas; Frédérique Léonard; Isabelle Ernens; Magali Rolland-Turner; Chantal Schwartz; Dan Longrois; Yvan Devaux; Daniel R Wagner
Journal:  Cardiovasc Res       Date:  2008-07-24       Impact factor: 10.787

8.  Adenosine receptors in regulation of dendritic cell differentiation and function.

Authors:  Sergey V Novitskiy; Sergey Ryzhov; Rinat Zaynagetdinov; Anna E Goldstein; Yuhui Huang; Oleg Y Tikhomirov; Michael R Blackburn; Italo Biaggioni; David P Carbone; Igor Feoktistov; Mikhail M Dikov
Journal:  Blood       Date:  2008-06-17       Impact factor: 22.113

9.  Cervical cancer cells produce TGF-β1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-β1.

Authors:  Rosario García-Rocha; Alberto Monroy-García; Jorge Hernández-Montes; Benny Weiss-Steider; Vianey Gutiérrez-Serrano; María Del Carmen Fuentes-Castañeda; Luis Roberto Ávila-Ibarra; Christian Azucena Don-López; Daniela Berenice Torres-Pineda; María de Lourdes Mora-García
Journal:  Cytokine       Date:  2018-10-06       Impact factor: 3.861

Review 10.  In vivo Differentiation of Human Monocytes.

Authors:  Alice Coillard; Elodie Segura
Journal:  Front Immunol       Date:  2019-08-13       Impact factor: 7.561

View more
  2 in total

Review 1.  Turning enemies into allies-reprogramming tumor-associated macrophages for cancer therapy.

Authors:  Martina Molgora; Marco Colonna
Journal:  Med (N Y)       Date:  2021-06-15

Review 2.  Angiogenic Properties of NK Cells in Cancer and Other Angiogenesis-Dependent Diseases.

Authors:  Dorota M Radomska-Leśniewska; Agata Białoszewska; Paweł Kamiński
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.